bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S7 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S7. The relationship of the miR-155-5p/C/EBPβ signaling and IL-6 expression in macrophages.
Movie S2 from The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
Authors: Vercruysse Thomas , De Bie Jolien , Neggers Jasper E. , Jacquemyn Maarten , Vanstreels Els , Schmid-Burgk Jonathan L. , Hornung Veit , Baloglu Erkan , Landesman Yosef , Senapedis William , Shacham Sharon , Dagklis Antonis , Cools Jan , Daelemans Dirk
Published: April 2023

Movie S2
Figure S2 from The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6
Authors: Yin Yuan , Yao Surui , Hu Yaling , Feng Yuyang , Li Min , Bian Zehua , Zhang Jiwei , Qin Yan , Qi Xiaowei , Zhou Leyuan , Fei Bojian , Zou Jian , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S2. CRC-conditioned macrophages induce the in vitro chemoresistance in CRC cells.
Supplementary Figure 7 from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

Comparison between patients with ACC and benign adrenal disease with respect to creatine riboside, Feature 1, Feature 6, and NE-trimethlylysine that were detected in the tissue: (A) creatine riboside, (B) m/z 306.153, (C) m/z 334.186, and (D) NE-trimethyllysine.
Supplementary Figure 5 from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

Comparison between patients with ACC and benign adrenal disease with respect to the four unknown features that were validated: (A) m/z 334.186, (B) m/z 306.153, (C) m/z 209.030, and (D) m/z 427.231.
Supplementary Figure 3 from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

Figure 3
Supplementary Figure 1 from Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms
Authors: Patel Dhaval , Thompson Matthew D. , Manna Soumen K. , Krausz Kristopher W. , Zhang Lisa , Nilubol Naris , Gonzalez Frank J. , Kebebew Electron
Published: April 2023

PCA plots showing discrimination between patients with mitotane ingestion (blue) and without mitotane ingestion (red) in reverse phase (RP) in both (A) ESI and (B) ESI- mode. Supervised OPLS-DA plots showing differences between the two groups in both (C) ESI and (D) ESI- mode. S-plot correlative analysis showing significant variables not correlated with patients with mitotane ingestion (highlighted in red) in both (E) ESI and (F) ESI- mode.
Supplementary Table 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Supplementary Table 3. ROC curves correlating BCR-ABL/ABL levels at diagnosis with 8-year estimates of OS, TFS, FFS, EFS and Optimal Response
Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Supplementary Table 2. Outcome comparison in patients recruited to the IRIS, German CML IV and SCREEN studies
Supplementary Figures S1-S15 from Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis
Authors: Gausachs Mireia , Borras Ester , Chang Kyle , Gonzalez Sara , Azuara Daniel , Delgado Amador Axel , Lopez-Doriga Adriana , San Lucas F. Anthony , Sanjuan Xavier , Paules Maria J. , Taggart Melissa W. , Davies Gareth E. , Ehli Erik A. , Fowler Jerry , Moreno Victor , Pineda Marta , You Y. Nancy , Lynch Patrick M. , Lazaro Conxi , Navin Nicholas E. , Scheet Paul A. , Hawk Ernest T. , Capella Gabriel , Vilar Eduardo
Published: April 2023

Figures S1, S2, S3 and S4. APC and KRAS genotyping of crypts and bulk biopsies in adenomas from MAP, UPF, LS and cMMRD cases. Figures S5, S6 and S7. APC and KRAS genotyping of crypts and bulk biopsies in adenomas from SPO cases. Figure S8, S9 and S10. Hyerarchical clustering analysis of crypts based on KRAS genotyping results. Figure S11. Comparative analysis of mutant allele discrimination by (A) Light Cycler 480 (Roche) and (B) nanofluidic PCR using Dynamic array (Fluidigm). Figure S12. A. Comparative analysis of KRAS genotyping using whole genome amplified (WGA) DNA or pre-amplified DNA using 15 cycles of a nested PCR. Figure S13. Genotyping results including water controls of random KRAS hotspot mutation analysis after performing a pre-amplification step using a nested PCR apporach. Figure S14. Independent validation of KRAS hotspot mutation that have been detected by Nanofluidic Dynamic array using the Nanofluidic Digital PCR genotyping as an alternative approach. Figure S15. Independent validation of KRAS hotspot mutation that have been detected by Nanofluidic Dynamic array using the Nanofluidic Digital PCR genotyping as an alternative approach.
Supplementary Figure 5 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Figure 5. Nomograms predicting eight-year FFS probabilities according to BCR-ABL/GUSIS expression at diagnosis and the Sokal (panel A) or Hasford (panel B) prognostic scores were generated by stratifying patients for these variables and then using a modified Cox proportional hazard model. Differences observed between the various patient subgroups were statistically significant (p<0.001).
Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Figure 4. Evolution of BCR-ABL/ABL transcripts in CML patients displaying high (A) or low (B) BCR-ABL/GUSIS levels at diagnosis according to the FFS threshold indicated in Table 1. Asterisks in the upper graph indicate confirmed transcript values in two separate samples collected one month apart.
Supplementary Figure 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Figure 3. Eight-year estimates of OS (A), TFS (B), FFS (C) and EFS (D) in CML patients expressing high or low BCR-ABL/ABL at diagnosis. The endpoint-specific BCR-ABL/ABL thresholds identified in Supplementary Table 3 were used to divide patients in two groups exhibiting high (dashed line) or low (solid line) BCR-ABL transcripts. Higher BCR-ABL levels were associated with significantly inferior rates of FFS (p<0.005) and EFS (p=0.001) but not OS and TFS. Vertical lines indicate censored patients.
Supplementary Figure 1-2 from CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study
Authors: Ng Chaan S. , Zhang Zheng , Lee Susanna I. , Marques Helga S. , Burgers Kyle , Su Feng , Bauza Joseph , Mannel Robert S. , Walker Joan L. , Huh Warner King , Rubin Stephen C. , DiSilvestro Paul , Martin Lainie P. , Chan John K. , Bookman Michael A. , Coleman Robert L. , Lee Ting-Yim
Published: April 2023

Figure S1. ACRIN 6695 plus RECIST CT scan schema; Figure S2. Kaplan-Meier PFS curve for patients who received bevacizumab and had increase vs. decrease in BF from T0 to T2.
Supplementary figures s1-s15 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Figure S1: Coefficient of variation telomerase assay. Figure S2: Telomerase assay controls Figure S3; Serial dilution, limit of detection telomerase assay, Figure S4; Protein extraction and assay performance; Figure S5; Lack of telomerase activity in supernatants. Figure S6; input protein and telomerase activity. Figure S7; Discovery set cyst fluid results effects of thawing. Figure S8 discovery set cyst fluid results. Figure S9 validation set results. Figure S10; telomerase results in previously thawed cyst fluids. Figure S11; Telomerase activity in all discovery set samples. Figure S12; Effect of cyst fluid on telomerase activity. Figure S13; SCN telomerase activity and cyst fluid appearance. Figure S14; Pathologic diagnosis according to cyst imaging group (high risk, worrisome etc). Figure S15: telomerase activity in EUS FNA samples
Supplementary Table S6 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Supplementary Table S6; Description of cases that provided endoscopically aspirated cyst fluid samples during their preoperative EUS examination.
Supplementary Table S3 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Supplementary Table S3; Diagnostic performance of telomerase activity comparing to the multiple imaging and clinical factors among 84 cases without prior thawing in the discovery set.
Supplementary Figure Legends from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Figure 1. Survival plot using Kaplan-Meier survival analysis between two patient groups with high- and low-heterogeneity. Supplementary Figure 2. Circle chart of the number of KRAS and TP53 mutation occurrences belonging to the four categories of CCFs. The four categories are based on CCF distribution (G1: 1st quantile, G2: 2nd quantile, G3: 3rd quantile, and G4: 4th quantile). Supplementary Figure 3. Signatures of mutational processes in oligo- and multi-clones. Each signature was extracted by decomposing the patterns of mutations.
Figure S3 from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Figure 3. Signatures of mutational processes in oligo- and multi-clones. Each signature was extracted by decomposing the patterns of mutations.
Figure S2 from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Figure 2. Circle chart of the number of KRAS and TP53 mutation occurrences belonging to the four categories of CCFs. The four categories are based on CCF distribution (G1: 1st quantile, G2: 2nd quantile, G3: 3rd quantile, and G4: 4th quantile).
Supplementary Material UNMARKED from Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
Authors: Apellániz-Ruiz María , Tejero Héctor , Inglada-Pérez Lucía , Sánchez-Barroso Lara , Gutiérrez-Gutiérrez Gerardo , Calvo Isabel , Castelo Beatriz , Redondo Andrés , García-Donás Jesús , Romero-Laorden Nuria , Sereno María , Merino María , Currás-Freixes María , Montero-Conde Cristina , Mancikova Veronika , Åvall-Lundqvist Elisabeth , Green Henrik , Al-Shahrour Fátima , Cascón Alberto , Robledo Mercedes , Rodríguez-Antona Cristina
Published: April 2023

Supplementary Table 1. Non synonymous coding and splicing site variants in the discovery series targeted sequencing. Supplementary Table 2. Association of common non-synonymous coding variants with paclitaxel-induced neuropathy.
Supplementary Tables 1-4, Supplementary Figures 1-3, Supplementary Methods from Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes
Authors: Li Jingmei , Ivansson Emma , Klevebring Daniel , Tobin Nicholas P. , Lindström Linda Sofie , Holm Johanna , Prochazka Gabriela , Cristando Camilla , Palmgren Juni , Törnberg Sven , Humphreys Keith , Hartman Johan , Frisell Jan , Rantalainen Mattias , Lindberg Johan , Hall Per , Bergh Jonas , Grönberg Henrik , Czene Kamila
Published: April 2023

Supplementary Table 1. List of 516 deep-sequenced cancer-related genes; Supplementary Table 2. Clinicopathological characteristics of screen-detected (n=109) versus interval breast cancers (n=111) in the validation dataset; Supplementary Table 3. Correlation between gene expression clusters and different Characteristics; Supplementary Table 4. Results of gene set enrichment analysis (GSEA Preranked); Supplementary Figure 1. Flow diagram leading to analytical cohort in discovery study; Supplementary Figure 2. Chromosomal plots for copy number aberrations; Supplementary Figure 3: Transcriptome profile of 111 interval breast versus 109 screendetected breast cancers in the validation dataset.
Supplementary Table 1 from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

Engraftment of human PBMCs in NOG-dKO mice after transplantation.
Supplementary Fig. 2 from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

Survival benefit in humanized NOG-dKO mice compared with humanized control NOG mice.
Supplementary Figures and Tables from Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Authors: Poulsen Thomas Tuxen , Grandal Michael Monrad , Skartved Niels Jørgen Østergaard , Hald Rikke , Alifrangis Lene , Koefoed Klaus , Lindsted Trine , Fröhlich Camilla , Pollmann Sofie Ellebæk , Eriksen Karsten Wessel , Dahlman Anna , Jacobsen Helle Jane , Bouquin Thomas , Pedersen Mikkel Wandahl , Horak Ivan David , Lantto Johan , Kragh Michael
Published: April 2023

Suppl. Figure 1 In vivo efficacy of Sym015 treatment at various dose levels in the EBC-1 xenograft model. Suppl. Figure 2 In vivo efficacy of Sym015 and unbalanced mixtures of the two constituent antibodies Hu9006 and Hu9338, applied at 10 mg/kg or 50 mg/kg doses in the EBC-1 xenograft model. Suppl. Figure 3 In vivo efficacy of Sym015 treatment in the H596 CDX model, which harbors a MET exon 14 deletion without MET gene amplification. Suppl. Figure 4 2 Map of clinically relevant mutations, obtained from the Cancer Cell Line Encyclopedia(31), in 64 cell lines. Suppl. Table S1 List of the 64 cell lines used in the study with information on tissue of origin, supplier, and growth medium used for propagation. Suppl. Table S2 Yellow columns: FISH scores for CDX and PDX models, denoting the average number of MET and CEP7 signals per cell, the MET/CEP7 ratio, and the percentage of tumor cells amplified. Suppl. Table S3 Prediction of human pharmacokinetics based on one-species allometric scaling(33).
Supplementary Table S1 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S1: Clinico-pathologic features and sequencing statistics of the 35 metaplastic breast cancers included in the study.
Supplementary Table 7 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Genes differentially expressed in ACEi alone treated group compared to control group
Supplementary Legends from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

File containing the legends for Supplementary Figures S1-S4 and Supplementary Tables S1-S6.
Supplementary Figure S3 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S3. Patterns of copy number alterations in metaplastic breast cancers (MBCs) and triple-negative invasive ductal carcinomas of no special type (IDC-NSTs) and unsupervised clustering of metaplastic breast cancers (MBCs) and triple-negative IDC-NSTs based on copy number alterations and somatic mutations. Frequency plot and multi-Fisher's exact test comparisons of copy number gains and losses in (a) MBCs and triple-negative IDC-NSTs and in (b) MBCs of triple-negative phenotype and triple-negative IDC-NSTs, and frequency plot and multi-Fisher's exact test comparisons of high-level gains/ amplifications and deletions in (c) MBCs and triple-negative IDC-NSTs and in (d) MBCs of triple-negative phenotype and triple-negative IDC-NSTs. In each panel (a-d), the frequency of gains/ high-level gains/ amplifications (purple bars) or losses/ deletions (orange bars) for each gene is plotted on the y-axis, according to their genomic position on the x-axis. Inverse Log10 values of the Fisher's exact test p-values are plotted according to genomic location (x-axis). Hierarchical clustering of (e) copy number alterations of MBCs and triple-negative IDC-NSTs using categorical states (i.e. gains, losses, amplifications and homozygous deletions) using Euclidean distance metric and the Wards algorithm, and of (f) somatic non-synonymous mutations and (g) somatic likely pathogenic mutations in genes found in at least one of the cancer gene lists (29-31) or were more frequently mutated in MBCs than triple-negative IDC-NSTs using an asymmetric binary distance metric and complete-linkage hierarchical clustering. Sample types, types of copy number alterations and the presence of somatic mutation in a given gene are color-coded according to the color key.
Supplementary Figure S2 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S2. Repertoire of somatic non-synonymous mutations of metaplastic breast cancers (MBCs) and triple-negative invasive ductal carcinomas of no special type (IDC-NSTs). Clinico-pathologic and immunohistochemical features, and non-synonymous somatic mutations somatic mutations identified in (a) 35 MBCs subjected to whole-exome sequencing, and in 69 triple-negative IDC-NSTs from TCGA breast cancer study (9) and in (b) 16, ten and nine chondroid, spindle and squamous MBCs, respectively, subjected to whole-exome sequencing. The effects of the mutations are colored-coded according to the legend, with hotspots colored in red. Mutations of indeterminate pathogenicity and likely passenger mutations are indicated by hatched boxes. The presence of multiple non-synonymous mutations in the same gene is represented by an asterisk. For MBCs, the presence of loss of heterozygosity of the wild-type allele of a mutated gene is represented by a diagonal bar, and mutations found to be clonal by ABSOLUTE (24) are indicated by a black box. Only recurrently mutated genes are presented (i.e. genes affected by non-synonymous somatic mutations in {greater than or equal to}2 MBCs). Gene names highlighted in purple were (a) significantly more frequently altered in MBCs or (b) differentially altered in the given subtype of MBC. Percentages to the right of the mutation heatmaps indicate the percentage of cases affected by non-synonymous somatic mutations in a given gene. Bar charts (top) indicate the number of non-synonymous and synonymous somatic single nucleotide variants (SNVs), and the number of somatic insertions and deletions (indels) for each sample. The dominant mutational signatures (35, 36) were assigned using deconstructSigs (37). Large-scale transitions (LST)-high and LST-low status was determined in accordance with Popova et al (39). TCGA, The Cancer Genome Atlas.
Supplementary Table 1-6 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Patient characteristics, unadjusted univariate model and adjusted analysis with multivariate model analyses in metastatic patients (supplementary table 1) and locally advanced patients (supplementary table 2) Supplementary Table 3: Unadjusted Univariate Analysis of Resected Patients with Hypertension Supplementary Table 4: Propensity score analysis Supplementary Table 5: Competing risk analysis in resected patients Supplementary Table 6: Multivariate model analysis of time to recurrence.
Supplementary Table 3 from T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy
Authors: Wang Tianjiao , Lu Ye , Polk Avery , Chowdhury Pinki , Zamalloa Carlos Murga , Fujiwara Hiroshi , Suemori Koichiro , Beyersdorf Niklas , Hristov Alexandra C. , Lim Megan S. , Bailey Nathanael G. , Wilcox Ryan A.
Published: April 2023

Supplementary Table 3 qPCR primer
Supplementary Table 1 from T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy
Authors: Wang Tianjiao , Lu Ye , Polk Avery , Chowdhury Pinki , Zamalloa Carlos Murga , Fujiwara Hiroshi , Suemori Koichiro , Beyersdorf Niklas , Hristov Alexandra C. , Lim Megan S. , Bailey Nathanael G. , Wilcox Ryan A.
Published: April 2023

Supplementary Table 1 Differentially expressed genes
Supplemental figures + legends from 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma
Authors: Kerk Samuel A. , Finkel Kelsey A. , Pearson Alexander T. , Warner Kristy A. , Zhang Zhaocheng , Nör Felipe , Wagner Vivian P. , Vargas Pablo A. , Wicha Max S. , Hurt Elaine M. , Hollingsworth Robert E. , Tice David A. , Nör Jacques E.
Published: April 2023

Supplementary Figure 1. PDX models of HNSCC express 5T4. Hematoxilin and eosin staining and immunohistochemistry for 5T4 (brown color) in PDX-SCC-M0, PDX-SCC-M1, and PDX-SCC-M11 models. Supplementary Figure 2. 5T4 expression co-localizes with cancer stem cells (i.e. CD44high) in HNSCC PDX tumors. Immunofluorescence of untreated PDX-SCC-M0 tumors showing 5T4 (red) and CD44 (green) expression patterns. White arrows point to 5T4 highCD44high cells. Supplementary Figure 3. Effect of MEDI0641 on HNSCC cell number in cell lines exhibiting intermediate (UM-SCC-74B) or low (UM-SCC-14B) 5T4 expression levels. Graphs showing the effect of 72-hour treatment with 0.5 or 1 μg/mL MEDI0641, as compared to 1 μg/mL IgG-PBD control, in UM-SCC-14B and UM-SCC-74B cells. Asterisks depict p<0.05. Supplementary Figure 4. MEDI0641 reduces the CSC fraction in the PDX-SCC-M11 model. (A) Figures showing the gating used for flow cytometry analysis of ALDH and CD44 activity in tumors treated with 1.0 mg/kg IgG1-PBD control or MEDI0641. A graph depicting the change in ALDH and CD44 activity in the IgG1-PBD control and MEDI0641 groups. (B) Graphs depicting the mean tumor volumes and mean mouse weights. of the IgG1-PBD control and MEDI0641 groups during the 7 day treatment period. (C) Actual pictures of the resected tumors from the IgG1-PBD control and MEDI0641 groups. Graphs depicting the tumor volumes and tumor weights of each tumor in the IgG1-PBD control and MEDI0641 groups. Supplementary Figure 5. MEDI0641 reduces the fraction of cancer stem cells. Graph displaying the effect of a single dose of 1 mg/kg MEDI0641 or 1 μg/mL IgG-PBD on the fraction of CD44high cells (FACS) in PDX-SCC-M11 tumors (7 days after injection). Supplementary Figure 6. MEDI0641 prevents local recurrence following surgery in the PDX-SCC-M11 model. A Kaplan-Meier curve depicting the results of a second independent recurrence experiment in mice treated with either IgG1-PBD control or MEDI0641 prior to surgical tumor removal.
Supplemental Figure 5B from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Representative Individual Concentration versus Time Pharmacokinetic Profiles for Total or Unbound Flavopiridol Using Bolus (A) or Hybrid (B) Dosing Schemes.
Supplemental Figure 3 from Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Authors: Khagi Yulian , Goodman Aaron M. , Daniels Gregory A. , Patel Sandip P. , Sacco Assuntina G. , Randall James M. , Bazhenova Lyudmila A. , Kurzrock Razelle
Published: April 2023

S. Figure 3 Landmark OS Total Alterations
Supplementary Figure S3 from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

RRM2 overexpression could not compensate for the RRM1 knockdown effect.
figure s3 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

Strategy for the evaluation of the early diagnostic accuracy of AC- and SCC-specific tumor-derived exosomal miRNAs in a symptomatic set
Supplementary Figure 1 legend from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
Authors: Palapattu Ganesh S. , Salami Simpa S. , Cani Andi K. , Hovelson Daniel H. , Lazo de la Vega Lorena , Vandenberg Kelly R. , Bratley Jarred V. , Liu Chia-Jen , Kunju Lakshmi P. , Montgomery Jeffery S. , Morgan Todd M. , Natarajan Shyam , Huang Jiaoti , Tomlins Scott A. , Marks Leonard S.
Published: April 2023

Legend to for supplementary Figure 1
Supplementary Tables 1-3 from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Authors: Rosen Lee S. , Goldman Jonathan W. , Algazi Alain P. , Turner P. Kellie , Moser Brian , Hu Tianle , Wang Xuejing Aimee , Tuttle Jay , Wacheck Volker , Wooldridge James E. , Banck Michaela
Published: April 2023

Table S1. Treatment emergent adverse events regardless of causality in {greater than or equal to}10% of patients; Table S2. Best Overall Response; Table S3. Reasons for Emibetuzumab Discontinuation.
Supplementary Figure 1B from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Authors: Rosen Lee S. , Goldman Jonathan W. , Algazi Alain P. , Turner P. Kellie , Moser Brian , Hu Tianle , Wang Xuejing Aimee , Tuttle Jay , Wacheck Volker , Wooldridge James E. , Banck Michaela
Published: April 2023

Treatment duration by patient and emibetuzumab dose for emibetuzumab monotherapy (A) and emibetuzumab + erlotinib (B).
Table S1 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

qRT-PCR primers used in the study
Supplementary Figures 1-12, Supplementary Tables 1-2 from The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Authors: Ma Yufang , Wang Lihong , Neitzel Leif R. , Loganathan Sudan N. , Tang Nan , Qin Lili , Crispi Emily E. , Guo Yan , Knapp Stefan , Beauchamp R. Daniel , Lee Ethan , Wang Jialiang
Published: April 2023

Supplementary Figure 1. BET inhibition reduces MYC expression and MYC-dependent transcription; Supplementary Figure 2. BET inhibition impairs proliferation and survival of CRC cells; Supplementary Figure 3. Phosphorylation status of ERK in CRC cell lines; Supplementary Figure 4. BET inhibition sensitizes CRC cells to inhibitors of the MAPK pathway; Supplementary Figure 5. The combination of JQ1 and trametinib impairs colony formation in CRC cells; Supplementary Figure 6. Depletion of BRD4 sensitizes CRC cells to trametinib; Supplementary Figure 7. Knockdown of KRAS recapitulates the ability of MAPK pathway inhibitors to sensitize CRC cells to JQ1; Supplementary Figure 8. Response to JQ1 {plus minus} trametinib in DLD1 and derivative lines; Supplementary Figure 9. Response to JQ1 {plus minus} trametinib in RKO and derivative lines; Supplementary Figure 10. (A) MYC mRNA levels in RKO cells treated with 500 nmol/L JQ1 {plus minus} 50 nmol/L trametinib for 2 days; Supplementary Figure 11. Co-targeting of BET proteins and MEK effectively shifts expression of apoptotic regulators to promote apoptosis; Supplementary Figure 12. The combination of JQ1 and trametinib induced CRC xenograft tumor Regression; Supplementary Table 1. Real-time PCR primers used in this study; Supplementary Table 2. Genotypes and IC50 values for JQ1 and trametinib in CRC cell lines.
Supplemental Tables 1-4, Supplemental Figures 1-2 from Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer
Authors: Arbour Kathryn C. , Jordan Emmett , Kim Hyunjae Ryan , Dienstag Jordan , Yu Helena A. , Sanchez-Vega Francisco , Lito Piro , Berger Michael , Solit David B. , Hellmann Matthew , Kris Mark G. , Rudin Charles M. , Ni Ai , Arcila Maria , Ladanyi Marc , Riely Gregory J.
Published: April 2023

Supplemental Table 1: Tumor Mutational burden according to individual KRAS mutation. Supplemental Table 2: Multivariate Analysis of duration of platinum/pemetrexed chemotherapy in patients with KRAS-mutant NSCLC Supplemental Table 3: Multivariate Analysis of duration of immunotherapy in patients with KRAS-mutant NSCLC Supplemental Table 4: Multivariate Analysis of Overall Survival from start of Immunotherapy in patients with KRAS-mutant NSCLC Supplemental Figure 1: Duration of platinum/pemetrexed +/- bevacizumab therapy in subset of patients receiving first line therapy for Stage IV disease by KEAP1/NFE2L2 mutations. Supplemental Figure 2: Duration of immune checkpoint inhibitor for treatment of Stage IV disease by different co-occurring mutations (A, STK11 B, KEAP1 or NFE2L2, C, TP53)
Revised supplementary material unmarked from Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment
Authors: Saxena Roopali , Yang Chunhua , Rao Mukkavilli , Turaga Ravi Chakra , Garlapati Chakravarthy , Gundala Sushma Reddy , Myers Kimberly , Ghareeb Ahmed , Bhattarai Shristi , Kamalinia Golnaz , Bristi Sangina , Su Dan , Gadda Giovanni , Rida Padmashree C.G. , Cantuaria Guilherme H. , Aneja Ritu
Published: April 2023

This is a revised supplementary material file with unmarked changes.
Supplementary Table S5 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Results from the supervised analysis comparing the methylomes of RETM918T tumors with WT tumors.
Supplementary Table S4 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Clinico-histopathological and molecular characteristics of the discovery set.
Supplementary table and figure legends from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Supplementary table and figure legends
Supplementary Table S4 from Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma
Authors: Kang Hyunseok , Tan Marietta , Bishop Justin A. , Jones Siân , Sausen Mark , Ha Patrick K. , Agrawal Nishant
Published: April 2023

Supplementary Table S4 provides information on the spectra of mutations seen in MEC tumors of varying histologic grades.
Supplementary Figure 1-3 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Fig S1: Ibrutinib-induced cell death is influenced by CLL cell-intrinsic traits (relapsed CLL data): Fig. S2: The relationship of Ibrutinib-induced cell death and recurrent gene mutations in CLL: Fig. S3: Correlation between IC50 values to ibrutinib in pre- and post-treatment paired CLL samples
Supplementary materials, Supplementary Figures 1-2, Supplementary Tables 1-4 from Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Authors: Liu Zhenyu , Zhang Xiao-Yan , Shi Yan-Jie , Wang Lin , Zhu Hai-Tao , Tang Zhenchao , Wang Shuo , Li Xiao-Ting , Tian Jie , Sun Ying-Shi
Published: April 2023

Table S1. Demographic comparison between Primary and Validation cohorts; Table S2. Radiomics features associated with CRT outcome identified by two sample t-test and LASSO; Table S3. Related factors for pCR detection in LARC; Table S4. Statistical significance of the clinical information in the multivariate regression model; Figure S1. Recruitment pathway for patients in this study; Figure S2. Typical cases of pCR and non-pCR.
Supplementary methods and data from 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer
Authors: Sakellariou-Thompson Donastas , Forget Marie-Andrée , Creasy Caitlin , Bernard Vincent , Zhao Li , Kim Young Uk , Hurd Mark W. , Uraoka Naohiro , Parra Edwin Roger , Kang Ya'an , Bristow Christopher A. , Rodriguez-Canales Jaime , Fleming Jason B. , Varadhachary Gauri , Javle Milind , Overman Michael J. , Alvarez Hector A. , Heffernan Timothy P. , Zhang Jianhua , Hwu Patrick , Maitra Anirban , Haymaker Cara , Bernatchez Chantale
Published: April 2023

Supplementary material and method Supplementary Figure S1. Addition of a4-1BB does not lead CD8+ TIL into senescence. Supplementary Figure S2. Fold expansion of bulk and CD8+ PDAC TIL following the REP. Supplementary Figure S3. Level of MHC class I expression on PDAC tumor cell lines.
Supplemental Figure 4 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

PFS and RORP classifier
Supplementary materials and methods from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Supplementary materials and methods
Supplementary figure legends from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Supplementary figure legends
Supplementary Figure S8. from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

LncRNA-TTN-AS1 increases the expression and stability of FSCN1 mRNA in ESCC cell lines.
Supplemental Figure 6 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 6. The percentage of CTLA4+ CD8+ T cells is much lower than that of CTLA-4+ Treg cells in the large established B-cell lymphoma.
Supplementary Figure S4. from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Analysis of different RNAs levels in ESCC cell lines and tissues.
Supplementary Figure S2 from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

LncRNA-TTN-AS1 has no coding capability.
Supplemental Figure 3 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 3. Clophosome could deplete macrophage efficiently, without depleting DCs.
Supplemental Figure 1 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 1. The therapeutic effect of anti-CD20 is not CD4+ T cell-dependent.
Table S1. Genes in colorectal cancer liver metastases that were sequenced. from PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
Authors: Qian David C. , Xiao Xiangjun , Byun Jinyoung , Suriawinata Arief A. , Her Stephanie C. , Amos Christopher I. , Barth Richard J.
Published: April 2023

Genes in colorectal cancer liver metastases that were sequenced.
Figure S5 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S5 Figure S5. (A) Kaplan-Meier estimates for progression-free survival (PFS); patients were stratified according to the diploid (in red) or aneuploid (in blue) nature of their tumour. (B) Kaplan-Meier estimates for PFS according to the number of copy number alteration (CNA) clones: 1 clone (in red) or more than 1 (in blue). (C-D) Kaplan-Meier estimates for overall survival (OS); patients were stratified according to the number of large LOH (C) and the number of large deletions (D): high number (in blue) or low number (in red). (E) Kaplan-Meier estimates for OS; patients were stratified according to the diploid (in red) or aneuploid (in blue) nature of their tumour. (F) Kaplan-Meier estimates for OS according to the number of copy number alteration (CNA) clones: 1 clone (in red) or more than 1 (in blue). The cutoffs were those defined for PFS with the Cutoff Finder method. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; ns: not significant
Supplementary Materials and Methods from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Authors: Wang Jian , Yang Shouhui , He Peijun , Schetter Aaron J. , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Gaida Matthias M. , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Supplementary methods: Describes additional details of generation of stable NOSTRIN overexpressing cells, western blotting, measurement of Nitric Oxide production, Xcelligence real-time migration assay and Luciferase Reporter Assay; Supplementary figure legends
Supplementary Figure S1 and Supplementary Tables S1-2 from Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Authors: Suominen Mari I. , Fagerlund Katja M. , Rissanen Jukka P. , Konkol Yvonne M. , Morko Jukka P. , Peng ZhiQi , Alhoniemi Esa J. , Laine Salla K. , Corey Eva , Mumberg Dominik , Ziegelbauer Karl , Käkönen Sanna-Maria , Halleen Jussi M. , Vessella Robert L. , Scholz Arne
Published: April 2023

'Supplementary Figure S1 shows the efficacy of radium-223 in an abiraterone-resistant LuCaP 58 prostate cancer PDX model; Supplementary Table S1 shows the characteristics of LNCaP and LuCaP 58 prostate cancer growth in bone models in mice and responses to radium-223; Supplementary Table S2 shows responses of radium-223 and abiraterone in LuCaP 58 prostate cancer PDX model in mice.'
Supplementary Materials and Methods and Figure Legends from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Supplementary Materials and Methods and Figure Legends